Eurefrine has no thrombolytic effect. Eurefrine is a protein hydrolase extracted from human urine, which has a diastolic effect on arteries because it can convert kininogen into kinin and angiotensin, and can inhibit platelet aggregation and enhance the deformability and oxygen dissociation of red blood cells. In patients with cerebrovascular disease (disease of cerebral infarction) it can increase the oxygen supply to brain tissue, reduce the expansion of the area of cerebral infarction and improve the symptoms caused by cerebral infarction, so it has some therapeutic significance for cerebral infarction, but it is not an anticoagulant or thrombolytic drug, so it is difficult to play the role of thrombolytic treatment. It can be used for infarction in the brain, but for thromboembolism in other parts of the body, this drug is weak and cannot really play the role of anticoagulant and thrombolytic drug.